Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates
Nutrients 2026;18(2):271 6 Alswailmi FK, Shah SIA, Nawaz H, Al-Mazaideh GM
Common comorbidities include: Digestive issues: Irritable bowel syndrome (IBS), constipation, diarrhea, heartburn Skin reactions: Eczema, rosacea, hives, flushing Respiratory problems: Runny nose, congestion, asthma-like symptoms Neurological symptoms: Headaches, migraines, brain fog, anxiety, insomnia
Conclusion GI AEs are the most common effects of GLP-1 RAs and dual GIP/GLP-1 RAs, often manifesting during initiation and dose escalation
US$ 25.05
US$ 27.41
US$ 20.56
US$ 22.54
